	Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K
ACURA PHARMACEUT Form 8-K September 29, 2014	TCALS, INC
UNITED STATES	
SECURITIES AND EXC	CHANGE COMMISSION
WASHINGTON, D. C. 2	20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act Of 1934

September 29, 2014

Date of Report (Date of earliest event reported)

ACURA PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in Charter)

State of New York 1-10113 11-0853640 (State of Other Jurisdiction (Commission File Number) (I.R.S. Employer of Incorporation) Identification Number)

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

616 N. North Court, Suite 120

Palatine, Illinois 60067

(Address of principal executive offices) (Zip Code)

(847) 705-7709

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

	1.Title of Security (Instr. 3)	2. Transaction Date2A. Deemed (Month/Day/Year) Execution Date, if any (Month/Day/Year)	(Instr. 8)	Acq Disp	ecuritie uired (posed o tr. 3, 4	A) or f (D)	5. Amount of Securities Beneficially Owned	Ownership Form:	7. Nature of Indirect Beneficial Ownership
		(Mondification)	(A) or		, 1	ana 3)		or Indirect	
Code	V		Amount (D)	Pric	e		Reported	(I)	
COMMON STOCK	11/21/2016	M	1,500 (1)	A	\$0	85,378	Transaction(s) Postr. 3 and 4)	(Instr. 4)	
COMMON STOCK	11/21/2016	D D	1,500 (1)	D	\$ 8.15	83,878	D		
COMMON STOCK						772	I	BY WIFE	

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Code	Securities Acquired (A) or Disposed of (D) (Instr. 3, 4,	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)
				and 5)		

Edgar Filing: ACURA PHARMACEUTICALS, INC - Form 8-K

			Code V (A)	(D)	Date Exercisable	Expiration Date	Title	or Number of Shares
RESTRICTED STOCK UNIT	\$ 0 (2)	11/21/2016	M	1,500	(3)	(3)	COMMON STOCK	1,50

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

SCHRECK ERIC W C/O TRUSTCO BANK CORP NY 5 SARNOWSKI DRIVE GLENVILLE, NY 12302

SVP & Treasurer

Signatures

/S/ MICHAEL M. OZIMEK, BY POWER OF ATTORNEY

11/22/2016

Amour

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Reflects cash settlement of 1,500 restricted stock units that settled only for cash.
- (2) Each restricted stock unit represents a contingent right to receive a payment in cash equal to the value of one share of Issuer Common Stock on the settlement date.
- (3) The restricted stock units "vested" in whole November 19, 2016 and were settled in cash.

Remarks:

ADDITIONAL SHARES ACQUIRED BY REPORTING PERSON'S PARTICIPATION IN DIVIDEND REINVESTMENT

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3